In the high-tech, high-competition AI field, we are seeing new versions of models rolled out by the frontier companies (OpenAI, Google and Anthropic) every month and a half. I included a Release ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Anthropic co-founder Dario Amodei urges a deliberate slowdown in AI development, emphasizing ...

“Recursive self-improvement” is the idea that artificial intelligence could learn to build and train itself, creating exponential new progress — and risk. Jeff Clune, a computer scientist and ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

The up-to-$12 billion artificial intelligence (AI) drug discovery collaboration of Recursion, Roche, and its Genentech subsidiary marked a milestone Wednesday when plans were announced for Recursion ...

On Tuesday, the AI company Recursive Superintelligence announced a $410 million compute deal with Amazon Web Services. The company, which emerged from stealth in May with $650 million in funding, is ...

The US AI research company Anthropic has become known for building powerful AI models while simultaneously warning about their dangers. “We are not there yet, and recursive self-improvement is not ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

The companies at the frontier of artificial intelligence should be ready to slow down, one of the fastest-moving among them says. Anthropic, the maker of the Claude chatbot, has claimed AI systems may ...

RSI is also defined as an “AI system capable of fully autonomously designing and developing its own successor,” per Anthropic’s blog post. “We are not there yet, and recursive self-improvement is not ...

Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...